NEW YORK, June 9, 2021 /PRNewswire/ -- The dengue vaccine market is expected to grow by USD 132.90 million during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the dengue vaccine market in optimistic, probable, and pessimistic forecast scenarios.
This dengue vaccine market report encapsulates not only the healthcare industry value chain analysis but also features overall validation techniques employed for deriving the most accurate data insights. Request a Free Sample Report
The dengue vaccine market will witness a neutral impact during the forecast period owing to the widespread growth of the COVID-19 pandemic. As per Technavio's pandemic-focused market research, market growth is likely to increase in 2021 as compared to 2020.
With the continuing spread of the novel coronavirus pandemic, organizations across the globe are gradually flattening their recessionary curve by leveraging technology. Many businesses will go through response, recovery, and renewal phases. Building business resilience and enabling agility will aid organizations to move forward in their journey out of the COVID-19 crisis towards the Next Normal.
Key Considerations for Market Forecast:
Impact of lockdowns, supply chain disruptions, demand destruction, and change in customer behavior
Optimistic, probable, and pessimistic scenarios for all markets as the impact of pandemic unfolds
Pre- as well as post-COVID-19 market estimates
Quarterly impact analysis and updates on market estimates
Related Reports on Healthcare Include: Global Human Vaccine Market - Global human vaccine market is segmented by RoA (intramuscular, subcutaneous, oral, and others) and geography (North America, Europe, Asia, and ROW). Request a Free Sample Report
Global Human Combination Vaccines Market - Global human combination vaccines market is segmented by type (Inactivated vaccine and Live attenuated vaccine) and geography (North America, Europe, Asia, and ROW). Request a Free Sample Report
Major Three Dengue Vaccine Market Participants: BioNet-Asia Co. Ltd.: The company offers Nanotaxi formulated DNA vaccine that induces a strong immune response against dengue virus.
Chula VRC: The company offers the tetravalent dengue DNA vaccine that is designed as a consensus sequence to encode proteins (pre-membrane and envelope) for each dengue serotype.
Codagenix Inc.: The company offers a balanced, tetravalent Dengue vaccine based on contemporary strains of dengue, that is designed to protect both civilians and deploying troops against all four Dengue serotypes, without causing enhanced disease.
Get specific analysis on the criticality of inputs and factors of differentiation in the dengue vaccine market vendor landscape. Download a Free Sample Now!
Dengue Vaccine Market 2021-2025: Segmentation Dengue vaccine market is segmented as below:
The dengue vaccine market is driven by the rapid growth in disease prevalence. In addition, initiatives for dengue vaccine research and dengue immunization programs are expected to trigger the dengue vaccine market toward witnessing a CAGR of about 18% during the forecast period.
About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.